1 July 2026 - Thousands of patients with multiple sclerosis face the prospect of losing publicly funded access to vital medicines as pharmaceutical companies rebel at Australia’s “archaic pricing policy” in a significant deepening of the crisis engulfing the PBS.

About half of all multiple sclerosis patients in Australia with the most common form of the disease take monoclonal antibody drugs that are highly effective in preventing relapse and disability progression. Two of these medications, high-efficacy therapies Ocrevus and Kesimpta, have been on the PBS since 2018 and 2021 respectively. Ocrevus is the most widely prescribed drug for multiple sclerosis.

Read The Australian article